Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$2.23-2.6%$6.72$2.10▼$1,030.00$42.57M-2.2378,436 shs60,682 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO-2.62%-8.23%-59.23%-88.26%-98.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$2.23-2.6%$6.72$2.10▼$1,030.00$42.57M-2.2378,436 shs60,682 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO-2.62%-8.23%-59.23%-88.26%-98.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO 2.00Hold$1,018.7545,583.86% UpsideCurrent Analyst Ratings BreakdownLatest KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BION/AN/AN/AN/A$0.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)Latest KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A4/15/2026Q4 2025KALAKALA BIO-$8.50$0.86+$9.36$43.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BION/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO2.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO3018.59 million18.17 millionNot OptionableKALA HeadlinesRecent News About These CompaniesReviewing KALA BIO (NASDAQ:KALA) & Elicio Therapeutics (NASDAQ:ELTX)May 25, 2026 | americanbankingnews.comKALA BIO (NASDAQ:KALA) Rating Increased to Hold at Wall Street ZenMay 24, 2026 | americanbankingnews.comAnalysts Set KALA BIO, Inc. (NASDAQ:KALA) Price Target at $1,018.75May 19, 2026 | americanbankingnews.comKALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 markMay 8, 2026 | msn.comKALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)May 7, 2026 | marketbeat.comKALA BIO Announces Reverse Stock SplitMay 7, 2026 | globenewswire.comHow smart traders spot penny stock breakouts fastMay 1, 2026 | msn.comKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineApril 21, 2026 | globenewswire.comKala Bio Delays 2025 Annual Report FilingApril 6, 2026 | theglobeandmail.comKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ...April 1, 2026 | caledonianrecord.comCKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesApril 1, 2026 | globenewswire.comKALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveMarch 30, 2026 | globenewswire.comEXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchMarch 30, 2026 | benzinga.comRed Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | markets.businessinsider.comRed Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | globenewswire.comRed Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | newsfilecorp.comNAI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market NarrativeMarch 11, 2026 | markets.businessinsider.comKala Bio chases 'Palantir for biotech' dream with new AI platformMarch 11, 2026 | msn.comYounet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research AgentsMarch 11, 2026 | newsfilecorp.comNKala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesMarch 11, 2026 | globenewswire.comStock Trend Capital Provides Younet AI Investment UpdateMarch 9, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALA Company DescriptionsKALA BIO NASDAQ:KALA$2.23 -0.06 (-2.62%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.23 0.00 (0.00%) As of 05/29/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
